Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide plus dexamethasone in relapsed or refractory multiple myeloma
CTR20210452Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2021
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pomalidomide in multiple myeloma (MM), sponsored by Qilu Pharmaceutical. Started Mar 2021; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20210452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210452.